Calcitonin
ApprovedSmall molecule
Calcitonin is one of 143 small molecule programs targeting Granuloma. It is currently in Approved.
8
Indications
11
Total Trials
3
Active Trials
142
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
190 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 3
Proamatine
TakedaPhase 3
Calcitonin
TTarsa Therapeutics, Inc.
Approved
Minocin
TTriax
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Cesamet
BBausch Health Americas, Inc.
Phase 3
Genotropin
EMD SeronoPhase 3
Myrbetriq
AstellasPhase 2
Fampridine-SR
AAcorda Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spinal Cord Injury1 trial
Nephrogenic Diabetes Insipidus1 trial
6 more indications
Women1 trial
Inflammatory Bowel Disease1 trial
Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease
Completed·—·N/A·NCT00114803·66 enrolled
Granuloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calcitonin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTarsa Therapeutics, Inc.